Latest Breaking News On - Pik3ca alterations - Page 1 : comparemela.com

The EMA’s CHMP recommended capivasertib/fulvestrant for ER-positive, HER2-negative advanced breast cancer harboring PIK3CA, AKT1, or PTEN alterations.

Israel generalComunidad autonoma de catalunaMafalda oliveiraDepartment of medical oncology at vallHebron university hospitalHebron institute of oncology breast cancer groupEuropean medicines agencyMedicinal productsHuman useMedical oncologyHebron instituteBreast cancer groupEr positive breast cancerPik3ca alterationsAkt1 alterationsPten alterations